RBC Capital Maintains Outperform on Pacira BioSciences, Lowers Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has maintained an Outperform rating on Pacira BioSciences (NASDAQ:PCRX) but lowered the price target from $53 to $45.

March 01, 2024 | 3:35 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital maintains an Outperform rating on Pacira BioSciences but lowers the price target from $53 to $45.
While the maintenance of an Outperform rating indicates continued confidence in the company's performance, the reduction in price target could suggest a reassessment of near-term growth expectations or market conditions. This mixed signal might lead to short-term uncertainty among investors, potentially stabilizing the stock price as the market digests the implications.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100